LinusBio
New York, US · Founded 2020 · 31 employees on LinkedIn · 5 known investors
Find your way into LinusBio
LinusBio develops precision medicine diagnostics based on exposome sequencing to identify biomarkers for complex conditions including autism spectrum disorder, amyotrophic lateral sclerosis, inflammatory bowel disease, and other diseases. The company serves physicians and patients seeking earlier detection and intervention for conditions that historically lacked molecular diagnostic endpoints.
Founders & leadership
LinusBio was founded in 2020 by Manish Arora.
Investors · 5
Also in the syndicate · 1
Funding
SEC filings, press & company announcements$16M disclosed across 1 of 3 rounds · 2023
- Undisclosed amountSeries AApr 2023
Bow Capital (lead), GreatPoint Ventures (lead), Divergent Investments
Source ↗ - Undisclosed amountSeries AMar 2023Source ↗
- $16MSeries AJan 2023 · 3 sources
Bow Capital (lead), GreatPoint Ventures (lead), Divergent Investments, the David Bellet Family Office
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does LinusBio do?
- LinusBio develops precision medicine diagnostics based on exposome sequencing to identify biomarkers for complex conditions including autism spectrum disorder, amyotrophic lateral sclerosis, inflammatory bowel disease, and other diseases. The company serves physicians and patients seeking earlier detection and intervention for conditions that historically lacked molecular diagnostic endpoints.
- Who founded LinusBio?
- LinusBio was founded by Manish Arora in 2020.
- Who are LinusBio's investors?
- LinusBio's investors include Bow Capital, GPV, GreatPoint Ventures, Divergent Investments.
- How much funding has LinusBio raised?
- LinusBio has disclosed $16M raised across 1 of its 3 known rounds.
- Where is LinusBio headquartered?
- LinusBio is headquartered in New York, US.